Golotimod (TFA)
Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod TFA (SCV 07 TFA) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod TFA (SCV 07 TFA) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2) [1][2][3].
Product Specifications
CAS Number
2828433-07-2
Product Name Alternative
SCV 07 (TFA) ; Gamma-D-glutamyl-L-tryptophan (TFA)
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Bacterial; STAT
Type
Reference compound
Related Pathways
Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/golotimod-tfa.html
Solubility
10 mM in DMSO
Smiles
O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2.OC(C(F)(F)F)=O
Molecular Formula
C18H20F3N3O7
Molecular Weight
447.36
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
STAT3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Vascular endothelial growth factor receptor 2 (KDR), partial